Recombinant Cpn 0810 stimulates proinflammatory cytokine expression and apoptosis in human monocytes

YUYU CHEN1, BAIPING WU1, LIANGZHUAN LIU2, XIAOXING YOU2, LILI CHEN2, YIMOU WU2 and QIUGUI ZHANG3

1Department of Inspection, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013; 2Department of Pathogenic Biology, University of South China; 3Department of Inspection, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China

Received May 19, 2014; Accepted October 18, 2014

DOI: 10.3892/etm.2014.2111

Abstract. The aim of the present study was to express the recombinant Chlamydia pneumoniae (C. pneumoniae) protein, Cpn 0810, in Escherichia coli (E. coli) BL21, and investigate the effects of Cpn 0810 on inflammatory and apoptotic processes in human monocyteic (THP-1) cells. An ELISA was performed to detect the levels of the proinflammatory cytokines, tumor necrosis factor (TNF)-α and interleukin (IL)-6. In addition, Hoechst 33258 staining and annexin V binding analyses were performed to measure the rates of apoptosis. Purified glutathione S-transferase (GST)-Cpn 0810 recombinant proteins were obtained from the E. coli BL21 cells carrying the pGEX6p-2/Cpn 0810 plasmid, and were shown to stimulate the expression of TNF-α and IL-6 in the THP-1 cells in a dose- and time-dependent manner. TNF-α and IL-6 levels peaked at 24 h after GST-Cpn 0810 stimulation. Furthermore, GST-Cpn 0810 significantly promoted the apoptosis of THP-1 cells. In conclusion, recombinant GST-Cpn 0810 was shown to stimulate the expression of TNF-α and IL-6, inhibit proliferation and induce apoptosis in THP-1 cells. Therefore, Cpn 0810 may interact with host cells following C. pneumoniae infection, functioning as an important pathogenic factor.

Introduction

Chlamydia pneumoniae (C. pneumoniae) is a common respiratory pathogen that can cause a number of respiratory diseases, including pneumonia, asthma, chronic pharyngitis and chronic bronchitis (1-4). C. pneumoniae activates macrophages to produce proinflammatory cytokines, which may result in atherosclerosis. Although C. pneumoniae is a serious threat to human health, its underlying pathogenic mechanisms are not fully understood. It has, however, been hypothesized that C. pneumoniae secretes various toxic proteins.

It is widely accepted that gram-negative bacteria secrete proteins through type I-V secretion systems. The type III secretion system (T3SS) is an independent system, whose effector proteins can change cytoskeletal structures, destroy signal transduction pathways, suppress apoptotic activity and interfere with host transcriptional regulation (5-7). Techniques for the screening and identification of Cpn T3SS have become increasingly studied. Previous studies have shown that the coding sequences of T3SS effector proteins are always located next to the chaperones (8-15). The Cpn 0810 gene is adjacent to Cpn lcrH1, a chaperone homolog gene with Yersinia lcrH, and the Cpn 0810 gene family is located within the coding clusters of the T3SS. Therefore, Cpn 0810 has been hypothesized to be an effector of the T3SS (16-19).

In the present study, Cpn 0810 was cloned, expressed and purified from C. pneumoniae. The effects of Cpn 0810 on inflammatory and apoptotic processes in human monocyteic cells (THP-1) were investigated, with the aim to provide a basis for the further study of the pathogenic mechanisms underlying Cpn T3SS effector proteins.

Materials and methods

Strains, plasmids and cell lines. An Escherichia coli (E. coli) BL21 strain and the THP-1 cell line were provided by the Department of Pathogenic Biology, University of South China (Hengyang, China).

Gene amplification and recombinant plasmid construction. Amplification of Cpn 0810 was performed using polymerase chain reaction (PCR), based on the following primer pairs: P1, 5'-CGCGGATCCATGAACTAAAAAGCCCAAGAAAAC-3', and P2, 5'-TTTCTCTTTTGCGGCGCTACTCAGGCTTTTACAT-3'.

Amplification was performed in a final reaction volume of 50 µl, containing 39.6 µl ddH2O, 5 µl 10X Pfu buffer, 1 µl dNTP mix (10mM), 1 µl P1 primer, 1 µl P2 primer, 0.4 µl DNA Polymerase (5 units) and 2 µl Cpn templates. The amplifica-
tion conditions were as follows: Initial polymerase activation at 94°C (5 min); 30 cycles of 94°C (30 sec), 52°C (45 sec) and 72°C (3 min); and a final elongation step at 72°C for 10 min. Distilled water was used as a negative control. The amplification products (363 bp) were subjected to 1.0% agarose gel electrophoresis containing ethidium bromide.

The PCR products were digested with BamHI and NotI (Promega Corporation, Madison, WI, USA), and ligated into the pGEX6p-2 plasmid (GE Healthcare, Piscataway, NJ, USA). The recombinant plasmid was transformed into E. coli BL21 competent cells, and the positive clones were screened by PCR and sequencing.

Expression and purification of the recombinant protein. Positive E. coli BL21 colonies, containing pGEX6p-2/Cpn0810, were cultured in Luria-Bertani (LB) solid medium (with ampicillin) at 37°C overnight, after which the culture was transferred to fresh LB liquid medium (with ampicillin). When the optical density reached a wavelength of 600 nm, isopropyl β-D-1-thiogalactopranoside (IPTG) was added with a final concentration of 0.2 mM, and the culture was shaken at 30°C for 4 h. The bacteria were then collected, and phosphate-buffered saline (8 ml/g cells) and lysozyme (4.0 g/l) were added to the cell pellet. Following incubation at room temperature for 2 h, the cells were subjected to sonication (10 sec on, 10 sec off) 30 times using a MSE Soniprep 150 (SANYO, Osaka, Japan). Following centrifugation at 10,000 x g for 20 min at 4°C, the supernatant was purified using a glutathione S-transferase (GST) purification resin column (Novagen; Merck KGaA, Darmstadt, Germany), according to the manufacturer's instructions. The GST-Cpn 0810 recombinant protein was identified by western blot analysis using a mouse anti-Cpn AR39 primary antibody (1:2,000 dilution; ab190064, Abcam, Cambridge, MA, USA), and the protein concentration was detected using bicinchoninic acid kits (Pik-day Bio Co., Ltd., Beijing, China).

Cell culture and simulation. THP-1 cell lines were cultured in RPMI 1640 medium (GE Healthcare Life Sciences, Logan, UT, USA), supplemented with 10% fetal bovine serum (FBS; GE Healthcare Life Sciences) and 2 mmol/l glutamine, and grown in a humidified incubator at 37°C with 5% CO₂. For simulation, cells were seeded on plastic culture plates (Corning Inc., Corning, NY, USA) and cultured in 1% FBS overnight. Cells were then stimulated using specific concentrations of GST-Cpn 0810 for predetermined time periods.

ELISA analysis. THP-1 cells were cultured in suspension, at a density of 10⁶ cells/ml, and seeded on 24-well plates. The groups were treated with 0.5, 1, 2, 3, 4, 5 and 6 µg/ml GST-Cpn 0810 in serum-free culture medium for 24 h. Treatments of 5 µg/ml GST and distilled water were used as negative controls, while 0.1 µg/ml lipopolysaccharide (LPS) treatment was used as a positive control. After 24 h, the supernatant was collected for analysis of tumor necrosis factor (TNF)-α and interleukin (IL)-6 by ELISA (Jingmei Biological Engineering Co., Ltd., Shenzhen, China). When the optimal concentration of GST-Cpn 0810 treatment was determined, the cells were cultured with the specific concentration of GST-Cpn 0810 for 0, 6, 12, 24, 36 and 48 h before the culture supernatant was used for TNF-α and IL-6 analysis.

Hoechst 33258 staining. THP-1 cells were seeded on six-well plates, at a density of 5x10⁵ cells/ml, and stimulated with 0, 5 and 10 µg/ml GST-Cpn 0810 for 24 h. Apoptosis was subsequently analyzed using Hoechst staining kits (Beyotime Institute of Biotechnology, Haimen, China), according to the manufacturer's instructions.

Annexin V-fluorescein isothiocyanate-propidium iodide (FITC-PI) assay. THP-1 cells were seeded on six-well plates, at a density of 5x10⁵ cells/ml, and stimulated with 0, 5, 10, 15 and 20 µg/ml GST-Cpn 0810 for 18 h. The rates of apoptosis were analyzed using an annexin V-FITC apoptosis detection kit (KeyGen Biotech, Nanjing, China). Treatment with 5 µg/ml GST was used as negative control, 0.1 µg/ml LPS was used as a positive control and untreated cells were used as a blank control.

Statistical analysis. Data are expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). Paired t-test was used to analyze comparisons between groups, and for analysis of paired data. P<0.05 was considered to indicate a statistically significant difference.

Results

Cloning, expression and purification of recombinant GST-Cpn 0810. In order to obtain purified recombinant Cpn 0810, a pGEX6p-2/Cpn 0810 plasmid was constructed and transformed into E. coli BL21 cells. Following induction with 0.2 mM IPTG for 4 h, these cells were lysed and the supernatant was purified using a GST purification column. Western blot analysis was performed using anti-Cpn AR39 antibodies. A specific protein band was observed at approximately 42 kD, indicating the expression of recombinant GST-Cpn 0810 protein (Fig. 1A). This purified recombinant protein was used in the following experiments.

Recombinant GST-Cpn 0810 elevates the expression levels of proinflammatory cytokines in THP-1 cells. To investigate the effects of GST-Cpn 0810 on the inflammation of THP-1 cells, purified recombinant GST-Cpn 0810 was incubated with the cells and the levels of TNF-α and IL-6 were detected using ELISA. THP-1 cells were treated with GST-Cpn 0810 at gradient concentrations of 0.5, 1, 2, 3, 4, 5 and 6 µg/ml for 24 h. The expression levels of TNF-α and IL-6 were found to increase over the concentration range, 0.5-4 µg/ml GST-Cpn 0810, when compared with the blank control group. Expression peaked at 4 µg/ml, where the expression levels of TNF-α and IL-6 were 184.75±17.40 and 75.36±29.49 pg/ml, respectively (Fig. 1B and 1C). At higher concentrations of 5-6 µg/ml GST-Cpn, the expression levels of TNF-α and IL-6 were reduced when compared with the peak levels. Accordingly, a concentration of 4 µg/ml GST-Cpn was used in the following time-course experiments.

THP-1 cells were subsequently treated with 4 µg/ml GST-Cpn 0810 for 6, 12, 24, 36 and 48 h, and the supernatant was collected for the TNF-α and IL-6 assays. The results showed that the stimulated expression levels of TNF-α and
IL-6 were detectable 6 h after GST-Cpn 0810 treatment, peaking at 24 h (Fig. 2). Therefore, the results indicated that GST-Cpn 0810 may elevate the levels of TNF-α and IL-6 expression in a dose- and time-dependent manner.

Discussion

C. pneumoniae causes a variety of diseases in humans, including chronic infection, lung disease and cardiovascular disease; however, its pathogenic mechanism is not fully understood. Previous studies have shown that Cpn T3SS may play an important role in these pathogenic processes, and Cpn 0810 has been predicted to be one of its effector proteins.
In the present study, the Cpn 0810 gene was subcloned into the prokaryotic expression vector, pGEX6p-2, and successfully transformed into E. coli BL21 cells. The recombinant proteins were purified using a GST purification resin column, and applied to THP-1 cells in order to study the effects.

The Cpn 0810 recombinant protein was shown to stimulate THP-1 cells to produce proinflammatory cytokines, including TNF-α and IL-6, in a dose- and time-dependent manner. The TNF-α and IL-6 levels increased as the GST-Cpn 0810 concentrations were increased from 0.5 to 4 µg/ml. However, as the Cpn 0810 concentration continued to increase, the inflammatory cytokine levels decreased. These results indicated that high concentrations of GST-Cpn 0810 can have toxic effects in THP-1 cells, as evidenced by the decreased levels of inflammatory cytokines. Since the proinflammatory cytokine levels in the GST control group were similar to the negative control group, the possibility of direct induction of these proinflammatory cytokines by GST was excluded. Cpn 0810 may interact with the host cell and participate in pathogenic processes. The expression levels of proinflammatory cytokines were stimulated 6 h after the administration of GST-Cpn 0810, and peaked at 24 h, demonstrating the time-course of the inflammation-stimulating effects of Cpn 0810.

TNF-α and IL-6 are important inflammatory mediators. TNF-α exerts a wide range of biological effects, and is one of the main cytokines involved in inflammatory cascades. TNF-α plays a key role in the regulation of inflammatory processes in atherosclerosis, mainly through the TNF-receptor 1 (p55) signaling pathway (20-24). Early in inflammation, TNF-α can promote immune cells in response to the invasion of pathogenic microorganisms. In addition, high levels of TNF-α can induce the instability of atherosclerotic plaques. Therefore, TNF-α has been regarded as an inflammatory biological marker for atherosclerotic plaque inflammation. TNF-α has been shown to be produced by local atherosclerotic plaque macrophages, blood neutrophils and monocytes, particularly in cases of arterial injury, plaque rupture and ulceration (25). TNF-α also activates endothelial and white blood cells, promotes the aggregation of inflammatory cells and promotes the release of inflammatory mediators (26).

IL-6 is an additional inflammatory cytokine with a variety of biological functions, known to be involved in immune regulation and the inflammatory response. IL-6 can increase the activation of platelets and fibrinogen, leading to increased blood viscosity and endothelial damage (27). In addition, IL-6 is closely associated with TNF-α in the acute phase inflammatory response, where TNF-α induces IL-6 and other factors to stimulate the production of C-reactive protein (CRP) in the liver (28). Furthermore, IL-6 and CRP are independent risk factors for stroke and myocardial infarction. C. pneumoniae may stimulate smooth muscle cells to produce IL-6, and C. pneumoniae-infected mononuclear cells may also secrete IL-6 in response to pathological factors.

In a previous study, C. pneumoniae infection was hypothesized to increase the levels of TNF-α and IL-6, in which Cpn-Csp-Csp may play a key role.

Apoptosis is a gene-regulated process of programmed cell death. Through detecting atherosclerotic plaques in the coronary and carotid arteries using TUNEL, previous studies (31,32) found that there were DNA fragments in the damaged intima. These fragments, which indicated apoptotic processes, were not detected in healthy blood vessels. In the present study, GST-Cpn 0810 was shown to inhibit THP-1 cell proliferation by inducing apoptosis. When treated with GST-Cpn 0810, typical morphological changes of apoptosis, including cell shrinkage, nuclear fragmentation, cell foam and apoptotic body formation, were observed in the THP-1 cells. With annexin V-FITC apop-

![Figure 3. Hoechst 33258 staining of THP-1 cells in the (A) normal control, (B) GST-treated control, (C) 5 µg/ml GST-Cpn 0810 and (D) 10 µg/ml GST-Cpn 0810 groups (magnification, x1,000). THP-1 cells were stimulated with 0, 5 and 10 µg/ml GST-Cpn 0810 for 24 h, and Hoechst 33258 staining was performed to analyze apoptosis. GST, glutathione S-transferase.

![Figure 4. Annexin-V-FITC-PI staining of THP-1 cells treated with GST-Cpn 0810. THP-1 cells were stimulated with 1-5 µg/ml GST-Cpn 0810 or 0.1 µg/ml LPS for 24 h, stained with annexin-V-FITC-PI, and analyzed by fluorescence-activated cell sorting. The percentages of apoptotic cells were calculated and statistical analysis was performed. *P<0.05 and **P<0.01, vs. GST control group. FITC-PI, fluorescein isothiocyanate-propidium iodide; GST, glutathione S-transferase; LPS, lipopolysaccharide.](image-url)

462 CHEN et al: Cpn INDUCES INFLAMMATION AND APOPTOSIS
tosis detection kits, apoptotic processes were also detected at 24 h after GST-Cpn 0810 stimulation in these cells.

In conclusion, the results of the present study demonstrated that recombinant GST-Cpn 0810 induces the expression and secretion of the proinflammatory cytokines, TNF-α and IL-6, and promotes apoptotic processes in THP-1 cells. Therefore, Cpn 0810 may function as an important pathogenic factor in interactions with host cells. However, further studies are required to reveal the underlying mechanisms of these processes.

Acknowledgements

This study was supported by a grant from the National Natural Science Foundation of China (no. 30870134).

References

1. Lui G, Ip M, Lee N, et al: Role of ‘atypical pathogens’ among adult hospitalized patients with community-acquired pneumonia. Respiratory 14: 1098-1105, 2009.
2. Damy SB, Higuchi ML, Timenetsky J, et al: Mycoplasma pneumoniae and/or Chlamydia pneumoniae inoculation causing different aggravations in cholesterol-induced atherosclerosis in apoE KO male mice. BMC Microbiol 9: 194, 2009.
3. Papaetis GS, Anastasakou E and Orphanidou D: Chlamydia pneumoniae infection and COPD: more evidence for lack of evidence? Eur J Intern Med 20: 579-585, 2009.
4. Jupelli M, Shimada K, Chiba N, et al: Chlamydia pneumoniae infection in mice induces chronic lung inflammation, iBALT formation, and fibrosis. PLoS One 8: e77447, 2013.
5. Mota LJ and Cornelis GR: The bacterial injection kit: type III secretion systems. Ann Med 37: 234-249, 2005.
6. Mota LJ, Sorg I and Cornelis GR: Type III secretion: the bacteria-ekaryotic cell express. FEMS Microbiol Lett 252: 1-10, 2005.
7. Journet L, Hughes KT and Cornelis GR: Type III secretion: a secretory pathway serving both motility and virulence (review). Mol Membr Biol 22: 41-50, 2005.
8. Müller N, Sattelmacher F, Lugert R and Gross U: Characterization and intracellular localization of putative Chlamydia pneumoniae effector proteins. Med Microbiol Immunol 197: 387-396, 2008.
9. Stone CB, Johnson DL, Bulir DC, Gilchrist JD and Mahony JB: Characterization of the putative type III secretion ATPase CdsN (Cpn0707) of Chlamydia pneumoniae. J Bacteriol 190: 6580-6588, 2008.
10. Herrmann M, Schuhmacher A, Mühldorfer I, Melchers K, Prothmann C and Dammeyer S: Identification and characterization of secreted effectors of Chlamydia pneumoniae TW183. Res Microbiol 157: 513-524, 2006.
11. Cortes C, Rzomp KA, Tvnennier A, Scidmore MA and Wizel B: Chlamydia pneumoniae inclusion membrane protein Cpn0585 interacts with multiple Rab GTPases. Infect Immum 75: 5586-5596, 2007.
12. Luo J, Jia T, Zhong Y, Chen D, Flores R and Zhong G: Localization of the hypothetical protein Cpn0585 in the inclusion membrane of Chlamydia pneumoniae-infected cells. Microb Pathog 42: 111-116, 2007.
13. Kartagina AS, Alekseevskii AV, Spirin SA, Zigangirova NA and Gintsburg AL: Effector proteins of Clamidia. Mol Biol (Mosc) 43: 963-983, 2009 (In Russian).
14. Luo J, Jia T, Flores R, Chen D and Zhong G: Hypothetical protein Cpn0308 is localized in the Chlamydia pneumoniae inclusion membrane. Infect Immum 75: 497-503, 2007.
15. Flores R, Luo J, Chen D, Sturgeon G, Shiv Shankar P, Zhong Y and Zhong G: Characterization of the hypothetical protein Cpn1027, a newly identified inclusion membrane protein unique to Chlamydia pneumoniae. Microbiology 153: 777-786, 2007.
16. Fields KA and Hackstadt T: Evidence for the secretion of Chlamydia trachomatis Cpn by a type III secretion mechanism. Mol Microbiol 38: 1048-1060, 2000.
17. Lugert R, Kuhns M, Polch T and Gross U: Expression and localization of type III secretion-related proteins of Chlamydia pneumoniae. Med Microbiol Immunol 193: 163-171, 2004.
18. Beeckman DS, Geens T, Timmermans JP, Van Oostveldt P and Vanrompay DC: Identification and characterization of a type III secretion system in Chlamydia pneumoniae. Vet Res 39: 27, 2008.
19. Jamison WP and Hackstadt T: Induction of type III secretion by cell-free Chlamydia trachomatis elementary bodies. Microb Pathog 45: 435-440, 2008.
20. Häcker H and Karin M: Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13, 2006.
21. Pfeffer K: Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14: 185–191, 2003.
22. Perrins CJ and Bobryshev YV: Current advances in understanding of immunopathology of atherosclerosis. Virchows Arch 458: 117-123, 2011.
23. Hu S, Liang S, Guo H, et al: Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 288: 27039-27047, 2013.
24. Paladino N, Mul Fedele ML, Duhart JM, Marpegan L and Golombek DA: Modulation of mammalian circadian rhythms by tumor necrosis factor-α. Chronobiol Int: 1-12, 2014.
25. Li L, Li DH, Qu N, Wen WM and Huang WQ: The role of ERK1/2 signaling pathway in coronary microembolization-induced rat myocardial inflammation and injury. Cardiology 117: 207-215, 2010.
26. Tsato V, Zauli G, Rimondi E, et al: Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells. Mediators Inflamm 2013: 423407, 2013.
27. Johnston SC, Zhang H, Messina LM, Lawton MT and Dean D: Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum. Arterioscler Thromb Vasc Biol 25: 2648-2653, 2005.
28. Ricker PM, Rifai N, Stamper MJ and Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772, 2000.
29. Sharma J, Dong F, Pirbhai M and Zhong G: Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis. Infect Immun 73: 4414-4419, 2005.
30. Biasucci LM, Santamaria M and Liuzzo G: Inflammation, atherosclerosis and acute coronary syndromes. Minerva Cardioangiol 50: 475-486, 2002 (In Italian).
31. Geng YJ and Libby P: Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol 147: 251-266, 1995.
32. Hayakawa Y, Takemura G, Misao J, et al: Role of ‘atypical pathogens’ among adult hospitalized patients with community-acquired pneumonia. Respiratory 14: 1098-1105, 2009.